Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against V.F. Corporation (VFC) due to allegations of false and misleading statements regarding the company's turnaround plans, particularly affecting the Vans brand's revenue growth trajectory [3][4]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in VFC between October 30, 2023, and May 20, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against VFC, with a deadline of November 12, 2025, for investors to seek the role of lead plaintiff [1][5]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [2]. Group 2: Allegations Against VFC - The complaint alleges that VFC and its executives violated federal securities laws by failing to disclose the true state of the company's turnaround plans, particularly regarding the Vans brand [3]. - The company's reported fourth-quarter results for fiscal 2025 revealed a significant decline in Vans' growth, with losses worsening from 8% to 20% [4]. - Following the disclosure of these results, VFC's stock price fell from $14.43 to $12.15 per share, a decline of approximately 15.8% in one day [4].

Core Viewpoint - C3.ai, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its growth and the impact of its CEO's health on the company's performance [3][4]. Company Summary - The class period for the lawsuit is from February 26, 2025, to August 8, 2025 [3]. - Allegations include that C3 AI's management provided overly positive statements while concealing material adverse facts about the company's growth potential and the CEO's health issues [3]. - On August 8, 2025, C3 AI announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its revenue guidance for the full fiscal year 2026, attributing this to "the reorganization with new leadership" and the CEO's health [3]. - Following this announcement, C3 AI's stock price dropped from $22.13 per share to $16.47 per share, a decline of approximately 25.58% in just one day [3]. Next Steps for Shareholders - Shareholders who purchased shares during the specified class period are encouraged to register for the class action by October 21, 2025 [4]. - Registration allows shareholders to receive updates on the case and does not involve any cost or obligation [4]. Legal Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [5].

Core Viewpoint - The company, 卡倍亿, received an administrative regulatory measure decision from the Ningbo Securities Regulatory Bureau due to non-compliance with regulations regarding shareholder equity changes [1][2]. Group 1: Regulatory Actions - 卡倍亿 was ordered to correct its actions and engage in regulatory discussions following a violation of the "Management Measures for the Acquisition of Listed Companies" [2]. - The company must submit a written rectification report within ten working days of receiving the decision [2]. - The chairman and general manager, 林光耀, along with the board secretary and deputy general manager, 秦慈, are required to attend regulatory discussions [2]. Group 2: Shareholder Changes - On May 22, 2025, 卡倍亿's controlling shareholder, 宁波新协实业集团有限公司, increased its shareholding from 76,881,000 shares to 107,633,400 shares, raising its ownership percentage from 56.97% to 57.11% [1]. - The company failed to announce this change in shareholding as required when the percentage change reached an integer multiple of 1% [1]. Group 3: Previous Regulatory Issues - This is not the first time 卡倍亿 has faced regulatory scrutiny; the company received two warning letters within a month in the previous year regarding its executives [2]. - In April 2024, two executives received warning letters for engaging in short-term trading of company bonds, violating regulations [3]. - In May 2024, the deputy general manager, 秦慈, received a warning for purchasing company stock within 30 days prior to the annual report announcement, which also constituted a regulatory violation [3]. Group 4: Company Background - 卡倍亿 was listed on the Shenzhen Stock Exchange on August 24, 2020, with an initial public offering of 13.81 million shares at a price of 18.79 yuan per share [4]. - The total amount raised from the IPO was approximately 259.49 million yuan, with a net amount of about 215.88 million yuan after deducting issuance costs [4][5]. - The company has conducted multiple rounds of fundraising through convertible bonds, raising a total of approximately 1.067 billion yuan across three fundraising events [6][7].

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations against Hims is from April 29, 2025, to June 23, 2025 [2]. - The complaint claims that Hims engaged in deceptive promotion and selling of knockoff versions of Wegovy, risking patient safety [2]. - There is a substantial risk that the collaboration with Novo Nordisk could be terminated due to these practices [2]. - The positive statements made by the defendants regarding the company's business and operations were materially misleading and lacked a reasonable basis [2]. Group 2: Shareholder Information - Shareholders who purchased HIMS shares during the class period are encouraged to register for potential lead plaintiff appointment [1][3]. - The deadline for shareholders to register is August 25, 2025, and there is no cost or obligation to participate [3]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [3]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing allegations of providing misleading information regarding the safety and clinical trial protocol of its RP-A501 treatment, leading to significant stock price decline after the FDA placed a clinical hold on the study due to serious adverse events, including a participant's death [1]. Summary by Relevant Sections Allegations - The complaint states that Rocket Pharmaceuticals made overwhelmingly positive statements while concealing material adverse facts about RP-A501's safety and clinical trial protocol [1]. - The company amended the trial protocol to include a new immunomodulatory agent without informing shareholders, which misled investors into purchasing shares at inflated prices [1]. - Following the announcement of the FDA's clinical hold on May 27, 2025, due to a serious adverse event, Rocket's stock price plummeted from $6.27 to $2.33, a decline of approximately 37% in one trading day [1]. Class Action Details - Shareholders who purchased RCKT shares between February 27, 2025, and May 26, 2025, are encouraged to register for the class action lawsuit, with a deadline of August 11, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions [3].